Where is Xontogeny's headquarters located?

Xontogeny's headquarters is located in Boston (United States).

How big is Xontogeny's investment team?

Xontogeny has a team of 18, including 4 partners.

How many companies has Xontogeny invested in?

Xontogeny has invested in 28 companies, including Forge Biologics & Astria Therapeutics.

Which companies has Xontogeny invested in lately?

Zucara Therapeutics & CereVasc are the latest investments by Xontogeny.

How many exits has Xontogeny been involved in?

Xontogeny's portfolio has seen 4 IPOs and 6 acquisitions.

Xontogeny - 2026 Investor Profile, Portfolio, Team & Investment Trends

1. Forge Biologics

Developer of gene therapeutic solutions for treating multiple diseases. It has developed gene therapies that aim to help patients suffering from rare diseases. Products include FBX-101 which helps to treat infantile Krabbe diseases, FBX-201 for rare and monogenic diseases, and FBX-301 for rare & cancer diseases.

Key facts about Forge Biologics

Founded Year: 2020
Location: Columbus (United States)
Stage: Acquired
Total Funding till date: $330M
Employee Count: 434 as on Apr 30, 2026
Investors: RA Capital Management, MidCap Financial and 7 Others
Latest Funding Round: Series C, Sep 12, 2022, $*****
Highlight: Acquired

2. Astria Therapeutics

Developer of therapeutics for rare diseases. It offers a lead candidate STAR-0215 which is a monoclonal antibody inhibitor of plasma kallikrein for the treatment of hereditary angioedema, and allergic and immunological diseases.

Key facts about Astria Therapeutics

Founded Year: 2008
Location: Boston (United States)
Last Known Valuation: $*****
Stage: Acquired
Total Funding till date: $117M
Employee Count: 58 as on Apr 30, 2026
Investors: HHS, Xontogeny and 3 Others
Latest Funding Round: Post IPO, Jan 29, 2021, $*****
Highlight: Acquired

3. Apogee Therapeutics

Developer of therapeutics for immunological and inflammatory disorders. The company is advancing a pipeline of product candidates, which includes APG777, for the treatment of immunological, inflammatory disorders, and autoimmune disorders.

Key facts about Apogee Therapeutics

Founded Year: 2022
Location: Waltham (United States)
Stage: Public
Total Funding till date: $149M
Employee Count: 305 as on Apr 30, 2026
Investors: Fairmont, Orbimed and 5 Others
Latest Funding Round: Series B, Dec 07, 2022, $*****
Highlight: Public

4. Cargo Therapeutics

Developer of cell-based therapeutics for cancer treatment. It offers CAR T-cell therapies which include CD22 CAR T, and Multi-Specific CAR T drug candidates for the treatment of hematological malignancies, and solid tumors.

Key facts about Cargo Therapeutics

Founded Year: 2021
Location: San Mateo (United States)
Stage: Acquired
Total Funding till date: $200M
Employee Count: 31 as on Apr 30, 2026
Investors: Wellington, Piper Sandler and 13 Others
Latest Funding Round: Series A, Feb 09, 2023, $*****
Highlight: Acquired

5. TORL BioTherapeutics

Developer of antibody-based therapeutics for the treatment of cancer. The company's lead candidate, TORL-1-23, is a CLDN6-directed antibody-drug conjugate for patients across multiple cancer types. Also, it is developing a broad pipeline of novel preclinical ADCs and mAb in oncologic indications.

Key facts about TORL BioTherapeutics

Founded Year: 2019
Location: Los Angeles (United States)
Stage: Series C
Total Funding till date: $412M
Employee Count: 63 as on Apr 30, 2026
Investors: Cowen, Bristol-Myers Squibb and 8 Others
Latest Funding Round: Series C, Oct 07, 2025, $*****
Highlight: Editors' Pick

View the full list of portfolio companies

Xontogeny has invested in 28 companies over the last 9 years, with an average of 3 new investments annually in the last 5 years. Its most recent first time investment was in Zucara Therapeutics and most recent follow-on round was in CereVasc.

Here are Xontogeny's Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	0	0
2025	0	0	0
2024	3	1	4
2023	4	1	5
2022	4	1	5
2021	6	1	7
2020	3	0	3
2019	0	0	0
2018	0	0	0
2017	2	0	2

View all investments by Xontogeny

Xontogeny has made 11 investments in Series A stage with an average round size of $55.9M, 7 investments in Seed stage with an average round size of $6.59M, 2 investments in Series B stage with an average round size of $89M, 1 investment in Series C stage with an average round size of $189M and 1 investment in Unattributed stage.

Here are Xontogeny's investments by stage:

Stage of entry	No. of Investments
Series A	11
Seed	7
Series B	2
Series C	1
Unattributed	1

Note: We have considered here, only first round of investments

View all investments by Xontogeny

Xontogeny has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Consumer and Environment. Notably, it has invested in 27 Enterprise (B2B) companies, 27 Tech companies and 1 Tech hardware company.

Here are Xontogeny's investments by sector:

Sector	No. of Investments
Life Sciences	21
High Tech	2
Sustainability Tech	2
Consumer	1
Environment	1
Others	1

Note: We have considered here, only first round of investments

View all investments by Xontogeny

Xontogeny has made most investments in United States (20), followed by Canada where it has made 1 investment.

Here are Xontogeny's investments by geography:

Country	No. of Investments
United States	20
Canada	1
Switzerland	1

Note: We have considered here, only first round of investments

View all investments by Xontogeny

Xontogeny has not made any investment in 2026 so far.

Here are the most recent investments by Xontogeny:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
Nov 12, 2024	Zucara Therapeutics	Canada	Series B	9963	Sanofi
May 13, 2024	CereVasc	United States	Series B	1658	Bain Capital
Apr 24, 2024	Adaptilens	United States	Series A	9517	Pillar VC [+1]
Apr 03, 2024	Neurosterix	Switzerland	Series A	2605	Perceptive Advisors [+1]
Sep 27, 2023	Avalyn Pharma	United States	Series C	6833	Perceptive Advisors [+13]

See more recent investments made by Xontogeny

4 of Xontogeny's portfolio companies have become public. Avalyn Pharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Apr 2026 at marketcap of $753M and Apogee Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $809M.

Here are Xontogeny's portfolio companies that went public:

Filter this list

Company	IPO Date	First Invested on	First Round of Investment	Round Size
Avalyn Pharma	Apr 30, 2026	Sep 27, 2023	Series C	4385
Apogee Therapeutics	Jul 14, 2023	-	-	9589
LianBio	Nov 01, 2021	-	-	4181
Solid Biosciences	Jan 26, 2018	-	-	2817

View more details about public companies in Xontogeny's portfolio

6 companies from Xontogeny's portfolio have been acquired. The most recent acquisition was Surf Bio in Jan 2026 by Halozyme for $*****.

Here are Xontogeny's portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Surf Bio	Jan 28, 2026	Apr 12, 2022	Seed	2347
Astria Therapeutics	Oct 14, 2025	-	-	5557
Cargo Therapeutics	Jul 08, 2025	Feb 09, 2023	Series A	5370
Landos Biopharma	Mar 25, 2024	-	-	9381
Forge Biologics	Nov 13, 2023	Jul 21, 2020	Series A	2809

View all acquired companies in Xontogeny's portfolio

Xontogeny has a team of 18 members including 4 Partners and 2 Principals located in United States. Xontogeny's team does not sit on the board of any company as of now.

Here is a list of top team members in Xontogeny:

Name	Designation	Location	Board Memberships	Contact Details
Adam Stone	Partner	New York City	-	-
Gianna Hoffman Luca	Partner	San Francisco	-	-
Fred Callori	Partner	Boston	-	-
Joseph Edelman	Partner	New York City	-	-
Takeru Furuya	Principal	Cambridge	-	-
Maggie Clarkeson-Carroll	Principal	New York City	-	-

View team details of Xontogeny

Over the past 9 years, 106 investors have co-invested in Xontogeny's portfolio companies. This includes funds and angels.

Invested before Xontogeny: HHS, F-Prime Capital and 43 others have invested in rounds before Xontogeny. There are 4 companies where HHS has invested before Xontogeny and 1 company where F-Prime Capital has invested before Xontogeny.
Top Co-investors of Xontogeny: 47 investors entered a company along with Xontogeny. These include investors like Perceptive Advisors (4 companies).
Invested after Xontogeny: A total of 14 investors have invested in Xontogeny's portfolio after their investments. Top Investors include Perceptive Advisors (3 companies) and Citadel (2 companies).